BioSpace News Archive

Syndax Pharmaceuticals, Inc. today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5 , 2022.

Vaxxinity, Inc. (Nasdaq: VAXX) announced today that its next generation UB-612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase 3 trial.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.

Reaction Biology Corporation (“Reaction”) today announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg, Germany.

Genprex, Inc. today announced that its Executive Vice President will be providing an overview of the Company’s gene therapies for cancer and diabetes at the following investor conference in December 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022).

SeaStar Medical Holding Corporation today announced the appointment of Thomas R. Mullen as Vice President of Operations and Product Development.

Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced its sponsorship of the ASHP Advantage initiative to support pharmacy technician recruitment and retention.

RedHill Biopharma Ltd. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million.

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.